HOME >> MEDICINE >> NEWS
New SSRI effective for the treatment of moderate-to-severe premature ejaculation

A selective serotonin reuptake inhibitor (SSRI) developed specifically for the treatment of premature ejaculation is safe and effective for men severely affected by the condition, according to an Article in this week's issue of The Lancet.

Premature ejaculation is the most common form of male sexual dysfunction, affecting 21-33% of men. Although the condition is highly undertreated, SSRIs, which were developed to treat depression and other psychiatric disorders, are being increasingly used as unlicensed treatments for premature ejaculation based on their side-effect of delayed ejaculation. However, these drugs can have drawbacks such as psychiatric problems, skin reactions, changes in bodyweight, and sexual side-effects like loss of libido.

In the study Jon Pryor (University of Minnesota, Minneapolis, MN, USA) and colleagues combined the results of two trials testing the effectiveness of dapoxetine, a short-acting SSRI developed specifically for the treatment of premature ejaculation. The analysis involved over 2600 men with moderate to severe premature ejaculation and their partners. Patients were randomly assigned to receive placebo (870), 30 mg dapoxetine (874), or 60 mg dapoxetine (870) and were instructed to take a dose 1-3 hours before sexual intercourse. On average, at the start of the study, the men ejaculated under a minute after penetration. The researchers found that after 12 weeks the time to ejaculation was 1.75 minutes for placebo, 2.78 minutes for 30 mg dapoxetine, and 3.32 minutes for 60 mg dapoxetine.

Dr Pryor adds: "Dapoxetine also improved patients' perceptions of control over ejaculation, satisfaction with sexual intercourse, and overall impression of change in condition. Partners benefited through improved satisfaction with sexual intercourse."

Common side-effects of the drug were nausea, diarrhoea, headache and dizziness.


'"/>

Contact: Joe Santangelo
j.santangelo@elsevier.com
212-633-3810
Lancet
7-Sep-2006


Page: 1

Related medicine news :

1. New treatment effective in counteracting cocaine-induced symptoms
2. Osteoporosis screening and treatment may be cost-effective for selected older men
3. Study shows radiofrequency ablation highly effective in treating kidney tumors
4. New study examines effectiveness of tailored health messages
5. Scaling up HIV prevention programs is cost effective
6. New study shows Rescue Remedy is an effective all-natural stress, anxiety reliever
7. U of M researchers assess effectiveness of computerized physician order entry system
8. Nepalese researchers identify cost-effective treatment for drug-resistant typhoid
9. Meningitis: effectiveness of preventive vaccination demonstrated
10. U-M study finds lymphoma drug effective over long term
11. Chemotherapy may enhance the effectiveness of brain tumor vaccines

Post Your Comments:
(Date:10/20/2014)... 20, 2014 hc1.com today announced ... cloud solution that enables healthcare organizations of all ... healthcare-specific customer relationship management (“CRM”) solution. , Designed ... needs of the healthcare industry, the hc1 Healthcare ... and patients by combining healthcare CRM, HIPAA-compliant collaboration, ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 AttorneyOne.com, a recognized ... latest information from the FDA on Sit and Slim ... 10 not to purchase or use Sit and Slim II ... Slim II is promoted as weight loss product on various ... from the market in 2010 for safety reasons, can significantly ...
(Date:10/20/2014)... (PRWEB) October 20, 2014 National Teen Driver ... of the American Academy of Pediatrics (Ohio AAP, http://www.ohioaap.org ... in encouraging parents of teen drivers to talk to their ... road. , Motor vehicle crashes are the leading cause of ... drivers involved in fatal crashes, and 859 (42%) of those ...
(Date:10/20/2014)... Texas (PRWEB) October 20, 2014 Houston ... to present the key elements of his innovative ... professor to plastic surgery residents and faculty at ... , where he, too, was once a medical student. ... the largest private cosmetic plastic surgery practices in Texas, ...
(Date:10/19/2014)... 2014 Dr. Babatunde Osotimehin, Executive Director ... of a ceasefire agreement that is expected to lead ... who were kidnapped from the north-eastern Nigerian town of ... long enough, and it is high time they are ... Osotimehin. , "We owe it to these girls to ...
Breaking Medicine News(10 mins):Health News:Healthcare Relationship Management (HRM) Leader hc1.com® Launches hc1® Quick Start™ 2Health News:FDA Advises Not to Use Sit and Slim II: AttorneyOne Monitors and Keeps Consumers Informed 2Health News:Ohio AAP Promotes National Teen Driver Safety Week 2Health News:Plastic Surgeon Patronella Presents Artistically-Inspired Tummy Tuck Method to Future Generation of Plastic Surgeons in Texas 2
(Date:10/20/2014)... de octubre de 2014  PneumRx, Inc. ( ... la pulmonología intervencional, anunció hoy la conclusión de ... meses antes de lo programado. El Estudio Clínico RENEW ... de investigación (IDE) aprobada por la FDA (Administración ... espiral de reducción de volumen pulmonar PneumRx RePneu, ...
(Date:10/20/2014)... Oct. 20, 2014 Valeritas, Inc., a leader ... patients with Type 2 diabetes, announced today that it ... Award. The award was presented October 16 th ... Columbus, Ohio . The Cardinal ... a variety of metrics specifically targeted at the importance ...
(Date:10/20/2014)... 2014 Lpath, Inc. (NASDAQ: ... therapeutics, received official notification from the European Patent Office ... patent supporting its iSONEP™ and ASONEP™ programs. ... No. 2087002, claims compositions of matter related to ... compounds, iSONEP and ASONEP. Sonepcizumab is an antibody ...
Breaking Medicine Technology:PneumRx concluye inscripción en prueba fundamental RENEW 2PneumRx concluye inscripción en prueba fundamental RENEW 3Valeritas Receives 2014 Cardinal Health Supply Chain Excellence Award 2Valeritas Receives 2014 Cardinal Health Supply Chain Excellence Award 3Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 2Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 3Lpath Granted Key European Patent Related to iSONEP and ASONEP Programs 4
Cached News: